The future of these treatments in the first-line setting will depend on several phase III studies, explains Quinn. There is a phase III study accruing with bevacizumab (Avastin) and atezolizumab (Tecentriq) compared with sunitinib (Sutent). Another study is comparing the CTLA-4 inhibitor ipilimumab (Yervoy) plus nivolumab (Opdivo) in the first-line setting with sunitinib.

If either of those studies show inferiority for sunitinib, there will be a new first-line therapy in that regard. However, it is unknown how these therapies would stack up against cabozantinib (Cabometyx) as a single agent or in combination, states Quinn. There are combination studies with cabozantinib that are currently ongoing.

The future of these treatments in the first-line setting will depend on several phase III studies, explains Quinn. There is a phase III study accruing with bevacizumab (Avastin) and atezolizumab (Tecentriq) compared with sunitinib (Sutent). Another study is comparing the CTLA-4 inhibitor ipilimumab (Yervoy) plus nivolumab (Opdivo) in the first-line setting with sunitinib.

If either of those studies show inferiority for sunitinib, there will be a new first-line therapy in that regard. However, it is unknown how these therapies would stack up against cabozantinib (Cabometyx) as a single agent or in combination, states Quinn. There are combination studies with cabozantinib that are currently ongoing.